Reprieve Cardiovascular
Reprieve Cardiovascular Raises $61M in Series B
Reprieve Cardiovascular Raises $61M in Series B
Reprieve Cardiovascular has successfully raised $61M in a Series B at a $300M valuation led by New Enterprise Associates, Sofinnova Partners.
Company Overview
Reprieve Cardiovascular is a HealthTech company headquartered in Milford, MA, founded in 2018 with 70+ employees.
Developer of therapy for acute decompensated heart failure
Fundraising Details
- Amount Raised: $61M
- Round Type: Series B
- Valuation: $300M
- Date: 2025-09-29
- Investors: New Enterprise Associates, Sofinnova Partners
About Reprieve Cardiovascular
Developer of therapy for acute decompensated heart failure The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Milford, MA
- Founded: 2018
- Team Size: 70+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Reprieve Cardiovascular's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Reprieve Cardiovascular's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $300M valuation marks an important milestone for Reprieve Cardiovascular, positioning the company among notable players in the HealthTech industry.
Looking Ahead
With this new capital, Reprieve Cardiovascular is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-09-29. For more information about Reprieve Cardiovascular, visit their headquarters at Milford, MA.
Company Info
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free